Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CNBX Stock Summary
In the News
CEO of Cannabics Pharmaceuticals, Eyal Barad, to present at Edison Open Forum: Cannabinoids 2021
TEL AVIV, Israel and BETHESDA, Md., Oct. 19, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that Company CEO, Eyal Barad, will present at the upcoming Edison Open Forum: Cannabinoids 2021, taking place today, Wednesday, October 19 th.
Cannabics Pharmaceuticals Announces Two New Provisional Patents: Compositions and Methods For Treating Cancer
Cannabics Pharmaceuticals Inc. (OTC:CNBX), a global leader in the development of cancer-related cannabinoid-based medicine, announced on Monday that it has filed two new provisional patent applications on Compositions and Methods for treating cancer, including colorectal cancer and early intervention therapy for colorectal cancer patients. These patent applications are now part of the Cannabics growing IP portfolio comprising of eight patent families with five granted patents and 19 pending applications.
Cannabics Pharmaceuticals Files 2 Provisional Patents On Compositions and Methods for Treating Cancer
TEL AVIV, Israel and BETHESDA, Md., Oct. 18, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has filed 2 new Provisional Patent applications on Compositions and Methods for treating cancer, including colorectal cancer and early intervention therapy for colorectal cancer patients.
Cannabics Announces New Corporate Logo, New Website and New Company Presentation
TEL AVIV, Israel and BETHESDA, Md., Sept. 30, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine and a pioneer in the development of psychedelic inspired medicine, announced today that it has updated its corporate image with a new logo and a new website.
Gabriel Yariv, Executive Director of Cannabics Pharmaceuticals and Dr. David Sans will participate at the ICDP Summit in Boston
TEL AVIV, Israel and BETHESDA, Md., Sept. 22, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that the Company will present at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston.
Cannabics Pharmaceuticals hires Healthcare Investment Banker Dr. David Sans in New York to expand CNBX in Mental Health Diseases
TEL AVIV, Israel and BETHESDA, Maryland, Sept. 21, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the hire of Dr. David Sans FAARM, PhD, MBA in New York to expand its current pipeline of clinical development assets in Mental Health Diseases.
Neuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired Medicine
TEL AVIV, Israel and BETHESDA, Md., Sept. 13, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine and a pioneer in the development of psychedelic inspired medicine, announced today that Dr. Ilya Reznik (MD), a renowned Neuropsychiatrist, has joined the company as Head of Psychedelic Inspired Medicine.
World-Renowned Melanoma Expert Joins Cannabics Pharmaceuticals' Board of Advisors
TEL AVIV, Israel and BETHESDA, Maryland, Aug. 4, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that Prof. Caroline Robert (MD.
Cannabics Pharmaceuticals Appoints a Second Independent Board Member
TEL AVIV, Israel and BETHESDA, Maryland, July 20, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has appointed Dr. Gil Feiler to its Board of Directors as an Independent Director. Dr. Feiler, 62, who until now served as a Permanent Observer on the company's Board, is a world-renowned economist and currently serves also as the company's Head of Advisory Board.
Cannabics Pharmaceuticals Announces Appointment of New Independent Board Member
TEL AVIV, Israel and BETHESDA, Md., July 7, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has appointed Dr. Inbar Maymon-Pomeranchik to its Board of Directors as an Independent Director.
CNBX Financial details
CNBX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-08-31
Metric | History | 2019-08-31 | 2020-08-31 | 2021-08-31 | 2022-08-31 | 2023-08-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.01 | 0.01 | 0 | 0.02 | 0.05 | |
Net income per share | 1.03 | -2.78 | -2.16 | -3.08 | -0.42 | |
Operating cash flow per share | -2.8 | -2.47 | -2.16 | -1.37 | -0.01 | |
Free cash flow per share | -3 | -2.54 | -2.16 | -1.37 | -0.01 | |
Cash per share | 3.19 | 0.69 | 1.2 | 0.1 | 0.01 | |
Book value per share | 13.36 | 1.57 | 1.56 | -1.34 | -0.23 | |
Tangible book value per share | 9.86 | 1.57 | 1.56 | -1.34 | -0.23 | |
Share holders equity per share | 13.36 | 1.57 | 1.56 | -1.34 | -0.23 | |
Interest debt per share | 0.02 | 0.01 | 0.76 | 1.44 | 0.15 | |
Market cap | 34.44M | 25.7M | 23.55M | 4.16M | 149.14K | |
Enterprise value | 34.17M | 24.92M | 23.03M | 5.8M | 1.36M | |
P/E ratio | 30.39 | -8.26 | -9.46 | -1.1 | -0.04 | |
Price to sales ratio | 3.5K | 3.59K | 0 | 138.76 | 0.36 | |
POCF ratio | -11.13 | -9.26 | -9.45 | -2.48 | -1.33 | |
PFCF ratio | -10.4 | -9.01 | -9.44 | -2.47 | -1.33 | |
P/B Ratio | 2.34 | 14.56 | 13.04 | -2.55 | -0.07 | |
PTB ratio | 2.34 | 14.56 | 13.04 | -2.55 | -0.07 | |
EV to sales | 3.47K | 3.48K | 0 | 193.54 | 3.32 | |
Enterprise value over EBITDA | -11.04 | -3.44 | -7.32 | -1.67 | -1.65 | |
EV to operating cash flow | -11.04 | -8.98 | -9.24 | -3.45 | -12.11 | |
EV to free cash flow | -10.32 | -8.74 | -9.24 | -3.45 | -12.11 | |
Earnings yield | 0.03 | -0.12 | -0.11 | -0.91 | -24.88 | |
Free cash flow yield | -0.1 | -0.11 | -0.11 | -0.4 | -0.75 | |
Debt to equity | 0 | 0 | 0.48 | -1.08 | -0.67 | |
Debt to assets | 0 | 0 | 0.28 | 2.17 | 2.69 | |
Net debt to EBITDA | 0.09 | 0.11 | 0.16 | -0.47 | -1.47 | |
Current ratio | 9.81 | 2.04 | 1.25 | 0.08 | 0.09 | |
Interest coverage | -180.05 | -374.21 | -1.09K | -2.32K | -793.34 | |
Income quality | -2.73 | 0.37 | 0.78 | 0.45 | 0.03 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 150.52 | 182.78 | 0 | 58.57 | 2.22 | |
Research and developement to revenue | 156.84 | 235.08 | 0 | 39.5 | 1.05 | |
Intangibles to total assets | 0.25 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.07 | 0.03 | 0 | 0 | 0 | |
Capex to revenue | -22.03 | -10.58 | 0 | -0.06 | 0 | |
Capex to depreciation | -1.15 | -0.35 | 0 | -0.01 | 0 | |
Stock based compensation to revenue | 25.13 | 10.08 | 0 | 24.33 | 0.44 | |
Graham number | 17.57 | 9.91 | 8.71 | 9.62 | 1.47 | |
ROIC | -0.22 | -0.72 | -0.76 | -23.66 | 1.36 | |
Return on tangible assets | 0.1 | -1.4 | -0.81 | -4.65 | -7.43 | |
Graham Net | 1.51 | 0.32 | 0.14 | -1.89 | -0.27 | |
Working capital | 3.87M | 475.12K | 317.8K | -2.25M | -2.29M | |
Tangible asset value | 10.88M | 1.76M | 1.81M | -1.63M | -2.02M | |
Net current asset value | 3.87M | 475.12K | 317.8K | -2.25M | -2.29M | |
Invested capital | 0 | 0 | 0.48 | -1.08 | -0.67 | |
Average receivables | 255.87K | 218.4K | 178.34K | 142.57K | 87.69K | |
Average payables | 265.48K | 223.19K | 204.32K | 319.32K | 398.52K | |
Average inventory | -1.74M | -1.7M | -178.34K | -142.57K | -87.69K | |
Days sales outstanding | 10.55K | 7.77K | 0 | 984.1 | 84.19 | |
Days payables outstanding | 0 | 0 | 293.26 | 847.8 | 756.56 | |
Days of inventory on hand | 0 | 0 | -337.66 | -148.5 | -213.09 | |
Receivables turnover | 0.03 | 0.05 | 0 | 0.37 | 4.34 | |
Payables turnover | 0 | 0 | 1.24 | 0.43 | 0.48 | |
Inventory turnover | 0 | 0 | -1.08 | -2.46 | -1.71 | |
ROE | 0.08 | -1.76 | -1.38 | 2.31 | 1.84 | |
Capex per share | -0.2 | -0.07 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-11-30 for Q1
Metric | History | 2022-11-30 | 2023-02-28 | 2023-05-31 | 2023-08-31 | 2023-11-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0.03 | 11.33 | 0 | |
Net income per share | -0.29 | -1.34 | -0.02 | -64.99 | -0.01 | |
Operating cash flow per share | -0.08 | -0.01 | 0 | 2.32 | 0 | |
Free cash flow per share | -0.08 | -0.01 | 0 | 2.32 | 0 | |
Cash per share | 0.02 | 0.02 | 0 | 14.7 | 0 | |
Book value per share | -1.57 | -1.02 | -0.21 | -228.6 | -0.08 | |
Tangible book value per share | -1.57 | -1.02 | -0.21 | -228.6 | -0.08 | |
Share holders equity per share | -1.57 | -1.02 | -0.21 | -228.6 | -0.08 | |
Interest debt per share | 1.41 | 3.21 | 0.14 | -387.38 | 0.05 | |
Market cap | 4.98M | 191.39K | 191.8K | 149.14 | 333.13K | |
Enterprise value | 6.72M | 1.68M | 1.48M | 1.21M | 1.57M | |
P/E ratio | -3.38 | -0.02 | -0.28 | 0 | -0.47 | |
Price to sales ratio | 0 | 0 | 0.62 | 0 | 3.72 | |
POCF ratio | -51.94 | -10.33 | -10.32 | 0.01 | -4.64 | |
PFCF ratio | -51.94 | -10.33 | -10.32 | 0.01 | -4.56 | |
P/B Ratio | -2.52 | -0.1 | -0.1 | 0 | -0.16 | |
PTB ratio | -2.52 | -0.1 | -0.1 | 0 | -0.16 | |
EV to sales | 0 | 0 | 4.77 | 12.14 | 17.51 | |
Enterprise value over EBITDA | -22.14 | 0.77 | -11.12 | -0.47 | -11.82 | |
EV to operating cash flow | -70.09 | -90.82 | -79.62 | 59.17 | -21.79 | |
EV to free cash flow | -70.09 | -90.82 | -79.62 | 59.17 | -21.43 | |
Earnings yield | -0.07 | -13.71 | -0.9 | -3.85K | -0.54 | |
Free cash flow yield | -0.02 | -0.1 | -0.1 | 137.57 | -0.22 | |
Debt to equity | -0.89 | -0.77 | -0.7 | -0.67 | -0.63 | |
Debt to assets | 2.89 | 3.33 | 2.01 | 2.69 | 3.39 | |
Net debt to EBITDA | -5.74 | 0.68 | -9.68 | -0.47 | -9.31 | |
Current ratio | 0.04 | 0.04 | 0.14 | 0.09 | 0.06 | |
Interest coverage | -31.88 | 0.45 | 9.41 | 0.03 | -25.96 | |
Income quality | 0.27 | 0.01 | 0.12 | -0.04 | 0.4 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0.71 | 1.67 | 1.67 | |
Research and developement to revenue | 0 | 0 | 0.85 | 0.93 | 1.26 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0.02 | |
Capex to revenue | 0 | 0 | 0 | 0 | -0.01 | |
Capex to depreciation | 0 | 0 | 0 | 0 | -0.03 | |
Stock based compensation to revenue | 0 | 0 | 0.11 | 0.35 | 0.39 | |
Graham number | 3.22 | 5.55 | 0.29 | 578.18 | 0.1 | |
ROIC | 1.69 | -4.54 | 0.27 | -1.97 | 0.22 | |
Return on tangible assets | -0.6 | -5.68 | -0.26 | -1.15 | -0.46 | |
Graham Net | -2.02 | -1.23 | -0.26 | -267.77 | -0.09 | |
Working capital | -2.48M | -2.36M | -2.22M | -2.29M | -2.33M | |
Tangible asset value | -1.97M | -2.01M | -1.91M | -2.02M | -2.09M | |
Net current asset value | -2.48M | -2.36M | -2.22M | -2.29M | -2.33M | |
Invested capital | -0.89 | -0.77 | -0.7 | -0.67 | -0.63 | |
Average receivables | 79.43K | 69.59K | 182.87K | 199.63K | 81.95K | |
Average payables | 529.02K | 653.73K | 862.89K | 675.58K | 290.81K | |
Average inventory | -79.43K | -69.59K | -182.87K | -199.63K | -81.95K | |
Days sales outstanding | 0 | 0 | 88.4 | 85.15 | 69.73 | |
Days payables outstanding | 1.24K | 1.58K | 2.28K | 785.42 | 560.4 | |
Days of inventory on hand | -162.73 | -136.12 | -685.55 | -221.22 | -158.03 | |
Receivables turnover | 0 | 0 | 1.02 | 1.06 | 1.29 | |
Payables turnover | 0.07 | 0.06 | 0.04 | 0.11 | 0.16 | |
Inventory turnover | -0.55 | -0.66 | -0.13 | -0.41 | -0.57 | |
ROE | 0.19 | 1.3 | 0.09 | 0.28 | 0.09 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
CNBX Frequently Asked Questions
What is Cannabics Pharmaceuticals Inc. stock symbol ?
Cannabics Pharmaceuticals Inc. is a US stock , located in Bethesda of Md and trading under the symbol CNBX
What is Cannabics Pharmaceuticals Inc. stock quote today ?
Cannabics Pharmaceuticals Inc. stock price is $0.0159 today.
Is Cannabics Pharmaceuticals Inc. stock public?
Yes, Cannabics Pharmaceuticals Inc. is a publicly traded company.